Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yoshito Akagi

Showing results (211-220 of 261) with videos related to

Pageof 27
Sort By:
Oncology Letters|August 11, 2022
Hyperlipidemia as a risk factor for Trousseau syndrome-related cerebral infarction in patients with advanced gastrointestinal cancerToshimitsu Tanaka, Hiroyuki Suzuki, Keisuke Miwa, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|February 3, 2023
[Retrospective Analysis of Treatment Strategies for Local Recurrence following Radical Resection of Rectal Cancer]Junya Fukuda, Fumihiko Fujita, Yusuke Kawamoto, et al.
International Journal of Clinical Oncology|April 14, 2024
Incidence and molecular characteristics of deficient mismatch repair conditions across nine different tumors and identification of germline variants involved in Lynch-like syndromeTetsuya Ito, Tatsuro Yamaguchi, Kensuke Kumamoto, et al.
Anticancer Research|August 2, 2019
Expression of Matrix Metalloproteinases in Intraductal Papillary Mucinous Neoplasm of the PancreasMasanori Akashi, Toru Hisaka, Hisamune Sakai, et al.
International Journal of Clinical Oncology|May 21, 2017
A prospective study of XELIRI plus bevacizumab as a first-line therapy in Japanese patients with unresectable or recurrent colorectal cancer (KSCC1101)Koji Ando, Yasunori Emi, Toyokuni Suenaga, et al.
International Journal of Clinical Oncology|November 16, 2017
Correction to: S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102)Yuji Miyamoto, Akihito Tsuji, Hiroaki Tanioka, et al.
International Journal of Clinical Oncology|January 10, 2016
S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102)Yuji Miyamoto, Akihito Tsuji, Hiroaki Tanioka, et al.
International Journal of Clinical Oncology|March 20, 2020
Efficacy and feasibility of S-1 plus oxaliplatin (C-SOX) for treating patients with stage III colon cancer (KSCC1303): final analysis of 3-year disease-free survivalKoji Ando, Yasunori Emi, Nobutomo Miyanari, et al.
Anticancer Research|August 2, 2019
Clinicopathological Study of Resections of Intraductal Papillary Neoplasm of the Bile DuctToshihiro Sato, Toru Hisaka, Hisamune Sakai, et al.
International Journal of Clinical Oncology|June 4, 2015
Phase II trial of an alternating regimen consisting of first-line mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: FIREFOX plus bevacizumab trial (KSCC0801)Keisuke Miwa, Eiji Oki, Yasunori Emi, et al.
Pageof 27

Showing results (211-220 of 261) with videos related to

Sort By:
Pageof 27
Oncology Letters|August 11, 2022
Hyperlipidemia as a risk factor for Trousseau syndrome-related cerebral infarction in patients with advanced gastrointestinal cancerToshimitsu Tanaka, Hiroyuki Suzuki, Keisuke Miwa, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|February 3, 2023
[Retrospective Analysis of Treatment Strategies for Local Recurrence following Radical Resection of Rectal Cancer]Junya Fukuda, Fumihiko Fujita, Yusuke Kawamoto, et al.
International Journal of Clinical Oncology|April 14, 2024
Incidence and molecular characteristics of deficient mismatch repair conditions across nine different tumors and identification of germline variants involved in Lynch-like syndromeTetsuya Ito, Tatsuro Yamaguchi, Kensuke Kumamoto, et al.
Anticancer Research|August 2, 2019
Expression of Matrix Metalloproteinases in Intraductal Papillary Mucinous Neoplasm of the PancreasMasanori Akashi, Toru Hisaka, Hisamune Sakai, et al.
International Journal of Clinical Oncology|May 21, 2017
A prospective study of XELIRI plus bevacizumab as a first-line therapy in Japanese patients with unresectable or recurrent colorectal cancer (KSCC1101)Koji Ando, Yasunori Emi, Toyokuni Suenaga, et al.
International Journal of Clinical Oncology|November 16, 2017
Correction to: S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102)Yuji Miyamoto, Akihito Tsuji, Hiroaki Tanioka, et al.
International Journal of Clinical Oncology|January 10, 2016
S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102)Yuji Miyamoto, Akihito Tsuji, Hiroaki Tanioka, et al.
International Journal of Clinical Oncology|March 20, 2020
Efficacy and feasibility of S-1 plus oxaliplatin (C-SOX) for treating patients with stage III colon cancer (KSCC1303): final analysis of 3-year disease-free survivalKoji Ando, Yasunori Emi, Nobutomo Miyanari, et al.
Anticancer Research|August 2, 2019
Clinicopathological Study of Resections of Intraductal Papillary Neoplasm of the Bile DuctToshihiro Sato, Toru Hisaka, Hisamune Sakai, et al.
International Journal of Clinical Oncology|June 4, 2015
Phase II trial of an alternating regimen consisting of first-line mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: FIREFOX plus bevacizumab trial (KSCC0801)Keisuke Miwa, Eiji Oki, Yasunori Emi, et al.
Pageof 27